Clinical validation in the global nutraceutical market

The global nutraceutical market is expanding rapidly. Grand View Research estimates the market at USD 636.2 billion in 2025 and projects it to reach USD 1,151.5 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 7.7% from 2026 to 2033.

Dietary supplements represent one of the key areas of this market, with the global dietary supplements market estimated at USD 209.52 billion in 2025 and projected to reach USD 431.69 billion by 2033, with a CAGR of 9.5% from 2026 to 2033. [1,2]

These figures confirm the scale of the opportunity, but they also highlight a more demanding competitive environment. Every year, new products, ingredients and formulations enter a market where many solutions appear increasingly similar.

In this scenario, differentiation not only depends on packaging, trends or commercial communication. The real challenge is selecting a solution that can be registered, explained, positioned and defended across different markets.

Clinical validation is therefore becoming a key business criterion. Choosing scientifically supported products means working with formulations backed by data, giving partners and healthcare professionals greater confidence in what they offer and recommend.

A more competitive and fragmented market

The growth of the nutraceutical sector has created new opportunities and stronger pressure on differentiation. In many countries, formulations containing similar ingredients may coexist within the same therapeutic area, making it difficult to distinguish scientifically solid solutions from products built around temporary market trends.

This fragmentation is further complicated by regulatory, cultural and commercial differences between markets. Each country has its own requirements regarding product registration, approved claims, distribution channels and healthcare professional expectations.

In Europe, the dietary supplements market is estimated at USD 49.39 billion in 2025 and projected to reach USD 97.76 billion by 2033, with a CAGR of 9.0% from 2026 to 2033. [3] This means that growth in a strategic region also brings more competition, more regulatory attention and a greater need for evidence-based positioning.

The claim environment reinforces this point. In the European Union, health claims on food products must be backed by scientific evidence and assessed before they can be used in labelling, advertising or commercial communication. EFSA reports that, as of 2023, over 260 health claims had been approved, while more than 70% of evaluated claims had been rejected due to a lack of scientific evidence. [4].

In the United States, structure/function claims for dietary supplements are not pre-approved by FDA, but manufacturers must have substantiation that the claim is truthful and not misleading, notify FDA within 30 days after marketing the product with that claim and include the required disclaimer. [5]

Advertising risk is part of the same picture. The FTC reports that, since 1998, it has settled or adjudicated more than 200 cases involving false or misleading advertising claims about dietary supplements and other health-related products. [6]

Evidence becomes a business asset. It can influence market access, claim substantiation, healthcare professional engagement and portfolio differentiation.

What clinical validation really means

Clinical validation goes beyond associating a formulation with scientific literature. A product may include scientifically studied ingredients without necessarily being supported by a strong clinical formulation.

Validation requires consistency between several factors:

• biological rationale
• dosage
• ingredient synergy
• target population
• manufacturing quality
• formulation reproducibility

A scientifically grounded approach starts with a precise question: which clinical or physiological need is the formulation intended to support, and through which mechanism?
From this starting point, formulation choices are developed. Ingredients are selected because each component must serve a specific function within the formulation. In nutraceuticals, the value of a formulation often depends on the balance between ingredients, dosages and how the components work together.

The key question is whether the available evidence matches the formulation, the dosage, the target population and the intended positioning of the product.

Different levels of scientific evidence

Scientific evidence can vary significantly in quality and relevance.

Preclinical studies help clarify biological mechanisms. Observational studies provide information about associations or specific populations. Clinical trials evaluate the effects of an intervention under controlled conditions.

Systematic reviews and meta-analyses help interpret the overall body of available evidence.

This distinction has practical implications. Regulatory teams need evidence that supports the wording of a claim. Sales teams need clear arguments to explain the product. Healthcare professionals may ask for data on dosage, population, endpoints and consistency of results.

FDA guidance on dietary supplement claim substantiation highlights that the relationship between the evidence and the claim, the quality of the evidence and the totality of the evidence are central elements when assessing whether a claim is adequately supported. [7]

Scientific documentation should clearly explain why a formulation is relevant, which data support its intended use and how those data can be communicated responsibly across different markets.

From research to market readiness

One of the most important aspects of clinical validation is its connection with research and development.

In a more advanced approach, scientific evidence contributes to the formulation strategy from the very beginning.

This means studying ingredients and combinations in relation to the target clinical need, evaluating the available literature, understanding mechanisms of action and developing formulations consistent with the original scientific rationale.

Products developed according to solid scientific criteria can be explained more effectively, adapted more efficiently and positioned more clearly across different local contexts.

This is where clinical validation becomes part of market readiness. A strong product is supported by a coherent scientific dossier, clear positioning, claim strategy, medical education materials and tools that help bring the product to market with confidence.

Why it matters for international market development

Choosing a nutraceutical product means investing time, resources and reputation into building a market.

A scientifically weak product may create uncertainty during registration processes, limit the available claims, complicate sales force training and reduce the credibility of communication with physicians, pharmacists and other healthcare professionals.

A product supported by a clear scientific rationale allows for more effective communication with both patients and healthcare professionals. This remains an important differentiating element, especially in highly crowded categories.

The value of clinical validation can be seen across the whole launch process. It helps regulatory teams assess claim feasibility, gives marketing teams a stronger evidence-based positioning, provides sales teams with more credible arguments and supports healthcare professional engagement through clearer scientific communication.

Clinical validation helps reduce uncertainty, strengthen credibility and support long-term value creation.

Building value through evidence-based solutions

The future of nutraceuticals will increasingly depend on the ability of companies to develop credible, well-documented solutions aligned with real market needs. The real difference lies in the scientific pathway supporting a product’s development.

Lo.Li. Pharma International operates through a dedicated B2B model, collaborating with local companies who bring its products to their national markets. Its brands are present in 76 countries and are adapted to the clinical, regulatory and cultural needs of each region. The company also provides tailored end-to-end support, from product registration and strategic positioning to medical education and marketing tools.

This approach is supported by a therapeutic portfolio backed by more than 450 scientific studies and by a model that connects research, formulation development and international market support. For distributors, this means working with products that combine scientific grounding with the tools needed to build medical credibility and market adoption.

In a competitive global market, this combination of clinical evidence, formulation know-how and international support can help move from product selection to sustainable market development.

To explore how scientifically supported nutraceutical solutions can promote your market strategy, discover Lo.Li. Pharma International’s approach to international partnerships.